Product menu

SHINGRIX mechanism of action

SHINGRIX is designed to induce cellular and humoral immune responses to VZV1*

SHINGRIX is the first and only shingles vaccine to combine two components, a non-live antigen with an Adjuvant System.1,2*

Non-live Antigen/Adjuvant System icon Non-live Antigen/Adjuvant System icon

VZV = varicella zoster virus.
* Clinical significance has not been established.

Learn more about the design of SHINGRIX

Discover the components and the mechanism of action of SHINGRIX.

Patient icon

Start the conversation about shingles risk with your patients

Nearly everyone ≥50 years old should be protected against shingles.3

Learn more
Virus icon

Did you know age is the dominant driver of shingles?

Learn about age-related decline in immunity.4

Learn more
Patient icon

Explore SHINGRIX safety profile

The safety profile of SHINGRIX in adults aged ≥50 years was extensively studied in two large Phase III clinical trials (ZOE-50 and ZOE-70). It was also evaluated in immunocompromised patients aged ≥18 years by pooling data from six placebo-controlled clinical studies involving adults who were immunodeficient or immunosuppressed due to disease or therapy (referred to as immunocompromised). 

Learn more

References:

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  2. Lal H, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372(22):2087–2096.
  3. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.
  4. Harpaz R, et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1–30.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

10572 | 05/24